Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C : a national French retrospective study
© 2023. The Author(s)..
BACKGROUND: Niemann-Pick disease type C (NP-C) is a rare neurovisceral lysosomal lipid storage disease characterized by progressive neurodegeneration and premature death. While miglustat can stabilize neurological manifestations in later onset forms of NP-C, its efficacy in the early-infantile neurological form has not been demonstrated. In this observational retrospective study, we compared long-term neurodevelopmental outcome and survival between an untreated and a treated group of early infantile NP-C patients.
METHODS: Data available on all NP-C patients with early infantile neurological onset diagnosed in France between 1990 and 2013 were compiled. Patients with incomplete data or who had died from a systemic perinatal, rapidly fatal form were excluded.
RESULTS: Ten patients were included in the treated group (year of birth: 2006-2012), and 16 patients in the untreated group [born 1987-2005 (n = 15), 2012 (n = 1)]. The median age at neurological onset was 9 months (5-18) in the treated group, and 12 months (3-18) in the untreated group (p = 0.22). Miglustat therapy was started at a median age of 24.5 months (9-29) and median duration was 30 months (11-56). Gastrointestinal adverse events were reported in 7/10 patients on miglustat. All patients developed loss of psychomotor acquisitions or additional neurological symptoms despite miglustat therapy. The ages of developmental milestones and neurological involvement did not significantly differ between the two groups. Four patients in the untreated group were lost to follow up. The 22 remaining patients had died by the end of the study and no patient survived beyond the age of 7.4 years. The median survival age was 4.42 years in the untreated group and 5.56 years in the treated group; the Kaplan-Meier survival curves were not significantly different (log-rank test: p = 0.11).
CONCLUSIONS: Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
Orphanet journal of rare diseases - 18(2023), 1 vom: 21. Juli, Seite 204 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Freihuber, Cécile [VerfasserIn] |
---|
Links: |
---|
Themen: |
1-Deoxynojirimycin |
---|
Anmerkungen: |
Date Completed 24.07.2023 Date Revised 24.07.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s13023-023-02804-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM359803520 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM359803520 | ||
003 | DE-627 | ||
005 | 20231226081646.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s13023-023-02804-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1199.xml |
035 | |a (DE-627)NLM359803520 | ||
035 | |a (NLM)37480097 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Freihuber, Cécile |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C |b a national French retrospective study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.07.2023 | ||
500 | |a Date Revised 24.07.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a BACKGROUND: Niemann-Pick disease type C (NP-C) is a rare neurovisceral lysosomal lipid storage disease characterized by progressive neurodegeneration and premature death. While miglustat can stabilize neurological manifestations in later onset forms of NP-C, its efficacy in the early-infantile neurological form has not been demonstrated. In this observational retrospective study, we compared long-term neurodevelopmental outcome and survival between an untreated and a treated group of early infantile NP-C patients | ||
520 | |a METHODS: Data available on all NP-C patients with early infantile neurological onset diagnosed in France between 1990 and 2013 were compiled. Patients with incomplete data or who had died from a systemic perinatal, rapidly fatal form were excluded | ||
520 | |a RESULTS: Ten patients were included in the treated group (year of birth: 2006-2012), and 16 patients in the untreated group [born 1987-2005 (n = 15), 2012 (n = 1)]. The median age at neurological onset was 9 months (5-18) in the treated group, and 12 months (3-18) in the untreated group (p = 0.22). Miglustat therapy was started at a median age of 24.5 months (9-29) and median duration was 30 months (11-56). Gastrointestinal adverse events were reported in 7/10 patients on miglustat. All patients developed loss of psychomotor acquisitions or additional neurological symptoms despite miglustat therapy. The ages of developmental milestones and neurological involvement did not significantly differ between the two groups. Four patients in the untreated group were lost to follow up. The 22 remaining patients had died by the end of the study and no patient survived beyond the age of 7.4 years. The median survival age was 4.42 years in the untreated group and 5.56 years in the treated group; the Kaplan-Meier survival curves were not significantly different (log-rank test: p = 0.11) | ||
520 | |a CONCLUSIONS: Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C | ||
650 | 4 | |a Observational Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Early infantile | |
650 | 4 | |a Efficacy | |
650 | 4 | |a France | |
650 | 4 | |a Miglustat | |
650 | 4 | |a Niemann-Pick disease type C | |
650 | 4 | |a Paediatric | |
650 | 4 | |a Safety | |
650 | 4 | |a Survival | |
650 | 7 | |a miglustat |2 NLM | |
650 | 7 | |a ADN3S497AZ |2 NLM | |
650 | 7 | |a 1-Deoxynojirimycin |2 NLM | |
650 | 7 | |a 19130-96-2 |2 NLM | |
700 | 1 | |a Dahmani-Rabehi, Bahia |e verfasserin |4 aut | |
700 | 1 | |a Brassier, Anaïs |e verfasserin |4 aut | |
700 | 1 | |a Broué, Pierre |e verfasserin |4 aut | |
700 | 1 | |a Cances, Claude |e verfasserin |4 aut | |
700 | 1 | |a Chabrol, Brigitte |e verfasserin |4 aut | |
700 | 1 | |a Eyer, Didier |e verfasserin |4 aut | |
700 | 1 | |a Labarthe, François |e verfasserin |4 aut | |
700 | 1 | |a Latour, Philippe |e verfasserin |4 aut | |
700 | 1 | |a Levade, Thierry |e verfasserin |4 aut | |
700 | 1 | |a Pichard, Samia |e verfasserin |4 aut | |
700 | 1 | |a Sevin, Caroline |e verfasserin |4 aut | |
700 | 1 | |a Vanier, Marie T |e verfasserin |4 aut | |
700 | 1 | |a Héron, Bénédicte |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Orphanet journal of rare diseases |d 2006 |g 18(2023), 1 vom: 21. Juli, Seite 204 |w (DE-627)NLM163016410 |x 1750-1172 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2023 |g number:1 |g day:21 |g month:07 |g pages:204 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13023-023-02804-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 18 |j 2023 |e 1 |b 21 |c 07 |h 204 |